Full-Time
Confirmed live in the last 24 hours
Biotechnology firm specializing in genetic testing
$180k - $200kAnnually
Senior, Expert
Company Historically Provides H1B Sponsorship
Remote in USA
Remote role with field-based responsibilities requiring 3-4 days of travel per week.
You match the following Natera's candidate preferences
Employers are more likely to interview you if you match these preferences:
Natera focuses on genetic testing and diagnostics, utilizing cell-free DNA (cfDNA) testing to detect molecular residual disease (MRD) in cancer patients and assess organ health for transplant patients. Their offerings include the Signatera test for cancer and Panorama NIPT for prenatal screening, with a strong emphasis on personalized genetic counseling. Natera stands out by providing a wide range of specialized testing services directly to healthcare providers and patients, often reimbursed by insurance. The company's goal is to improve patient care and health outcomes through advanced genetic testing solutions.
Company Size
1,001-5,000
Company Stage
IPO
Total Funding
$149.9M
Headquarters
Austin, Texas
Founded
2004
Help us improve and share your feedback! Did you find this helpful?
Flexible medical plans
Investment options
Time off
Workplace perks
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2024, after the market closes on Feb. 27, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m
Alpha DNA Investment Management LLC invests $505,000 in Natera, Inc. (NASDAQ:NTRA).
Delap Wealth Advisory LLC makes new $454,000 Investment in Natera, Inc. (NASDAQ:NTRA).
In other recent news, Natera Inc. has launched the DECIPHER trial for gastroesophageal adenocarcinoma (EGC) treatment, utilizing its molecular residual disease (MRD) test, Signatera.
Donor Quantity Score (DQS) technique is unique to Natera, improving detection of both acute cellular rejection and antibody-mediated rejectionAUSTIN, Texas, June 17, 2024--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of Prospera Heart™ with Donor Quantity Score (DQS), further enhancing Prospera’s ability to detect rejection in heart transplant patients.Traditionally, donor-derived cell-free DNA (dd-cfDNA) tests have reported rejection risk based only on the fraction of dd-cfDNA in the blood vs. the total cfDNA (dd-cfDNA %). This fraction can be confounded by fluctuations in the amount of background total cfDNA (the denominator), which are sometimes caused by factors unrelated to the health of the transplant, including infection, surgery, or chemotherapy.Prospera Heart now incorporates a second metric – the DQS – that normalizes for the background total cfDNA. Prospera Heart with DQS combines the traditional donor fraction and the new DQS into a two-threshold algorithm, delivering a single result with more accurate risk assessment for both antibody mediated rejection (AMR) and acute cellular rejection (ACR)."Over the last two decades, Natera has pioneered cfDNA testing across women’s health, oncology, and transplant medicine," said Michael Olymbios, M.D., Medical Director, Heart Transplant. "Our extensive experience with cfDNA and Natera’s culture of continuous innovation drove us to further refine Prospera Heart by introducing this two-threshold algorithm to better serve the transplant community."A study performed at the University of Utah and the University of California San Diego showed that incorporating DQS enhanced the performance of Prospera Heart in screening for biopsy-proven active rejection